Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.
Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.